BOUT vs. IMCG
BOUT (Innovator IBD Breakout Opportunities ETF) and IMCG (iShares Morningstar Mid-Cap Growth ETF) are both Mid Cap Growth Equities funds - BOUT tracks the IBD Breakout Stocks Total Return Index while IMCG tracks the Morningstar US Mid Cap Broad Growth Index. Both are passively managed. Over the past 5 years, BOUT returned 8.25%/yr vs 8.62%/yr for IMCG. A 0.80 correlation means they provide meaningful diversification when combined. BOUT charges 0.80%/yr vs 0.06%/yr for IMCG.
Performance
BOUT vs. IMCG - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BOUT achieves a 31.39% return, which is significantly higher than IMCG's 20.05% return.
BOUT
- 1D
- -0.01%
- 1M
- 5.85%
- YTD
- 31.39%
- 6M
- 30.30%
- 1Y
- 35.27%
- 3Y*
- 17.42%
- 5Y*
- 8.25%
- 10Y*
- —
IMCG
- 1D
- -0.26%
- 1M
- 8.33%
- YTD
- 20.05%
- 6M
- 18.28%
- 1Y
- 23.35%
- 3Y*
- 18.91%
- 5Y*
- 8.62%
- 10Y*
- 14.46%
BOUT vs. IMCG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
BOUT Innovator IBD Breakout Opportunities ETF | 31.39% | -6.77% | 18.82% | 13.27% | -22.60% | 22.69% | 50.56% | 20.59% | -29.80% |
IMCG iShares Morningstar Mid-Cap Growth ETF | 20.05% | 6.55% | 18.14% | 20.73% | -25.79% | 15.39% | 45.64% | 35.70% | -17.84% |
Correlation
The correlation between BOUT and IMCG is 0.79, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.79 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.83 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.78 |
Correlation (All Time) Calculated using the full available price history since Sep 14, 2018 | 0.80 |
The correlation between BOUT and IMCG has been stable across timeframes, ranging from 0.78 to 0.83 - a consistent structural relationship.
BOUT vs. IMCG - Sectors Allocation Comparison
Sectors
BOUT
IMCG
Technology
Financial Services
Basic Materials
Consumer Defensive
Industrials
Consumer Cyclical
Utilities
Real Estate
Energy
Healthcare
Communication Services
Technology
BOUT
IMCG
Financial Services
BOUT
IMCG
Basic Materials
BOUT
IMCG
Consumer Defensive
BOUT
IMCG
Industrials
BOUT
IMCG
Consumer Cyclical
BOUT
IMCG
Utilities
BOUT
IMCG
Real Estate
BOUT
IMCG
Energy
BOUT
IMCG
Healthcare
BOUT
IMCG
Communication Services
BOUT
IMCG
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BOUT vs. IMCG — Risk / Return Rank
BOUT
IMCG
BOUT vs. IMCG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Innovator IBD Breakout Opportunities ETF (BOUT) and iShares Morningstar Mid-Cap Growth ETF (IMCG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BOUT | IMCG | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.19 | ||
| Sortino ratioReturn per unit of downside risk | +0.15 | ||
| Omega ratioGain probability vs. loss probability | 1.30 | 1.26 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 3.01 | 2.31 | +0.70 |
| Martin ratioReturn relative to average drawdown | 9.00 | 8.97 | +0.03 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BOUT | IMCG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.71 | 1.51 | +0.19 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.43 | 0.43 | 0.00 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.71 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.41 | 0.54 | -0.13 |
Drawdowns
BOUT vs. IMCG - Drawdown Comparison
The maximum BOUT drawdown since its inception was -36.75%, smaller than the maximum IMCG drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for BOUT and IMCG.
Loading charts...
Drawdown Indicators
| BOUT | IMCG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -36.75% | -58.96% | +22.21% |
Max Drawdown (1Y)Largest decline over 1 year | -11.76% | -10.17% | -1.59% |
Max Drawdown (3Y)Largest decline over 3 years | -25.31% | -21.92% | -3.39% |
Max Drawdown (5Y)Largest decline over 5 years | -28.28% | -35.08% | +6.80% |
Max Drawdown (10Y)Largest decline over 10 years | — | -35.08% | — |
Current DrawdownCurrent decline from peak | -0.01% | -0.26% | +0.25% |
Average DrawdownAverage peak-to-trough decline | -12.29% | -9.22% | -3.07% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.93% | 2.61% | +1.32% |
Volatility
BOUT vs. IMCG - Volatility Comparison
Innovator IBD Breakout Opportunities ETF (BOUT) has a higher volatility of 5.96% compared to iShares Morningstar Mid-Cap Growth ETF (IMCG) at 4.65%. This indicates that BOUT's price experiences larger fluctuations and is considered to be riskier than IMCG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BOUT | IMCG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.96% | 4.65% | +1.31% |
Volatility (6M)Calculated over the trailing 6-month period | 16.05% | 12.53% | +3.52% |
Volatility (1Y)Calculated over the trailing 1-year period | 20.79% | 15.53% | +5.26% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 19.48% | 20.17% | -0.69% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.93% | 20.51% | +2.42% |
BOUT vs. IMCG - Expense Ratio Comparison
BOUT has a 0.80% expense ratio, which is higher than IMCG's 0.06% expense ratio.
Dividends
BOUT vs. IMCG - Dividend Comparison
BOUT's dividend yield for the trailing twelve months is around 0.26%, less than IMCG's 0.65% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BOUT Innovator IBD Breakout Opportunities ETF | 0.26% | 0.34% | 0.60% | 1.32% | 1.35% | 0.00% | 0.00% | 0.00% | 0.22% | 0.00% | 0.00% | 0.00% |
IMCG iShares Morningstar Mid-Cap Growth ETF | 0.65% | 0.78% | 0.78% | 0.85% | 0.91% | 0.41% | 0.09% | 0.30% | 0.35% | 0.45% | 0.52% | 0.38% |
Frequently Asked Questions
BOUT and IMCG have a correlation of 0.79, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BOUT has higher volatility (5.96%) compared to IMCG (4.65%). In terms of maximum drawdown, BOUT dropped -36.75% vs IMCG's -58.96%.
On 5-year performance, IMCG leads with 8.62% vs 8.25% for BOUT. On fees, IMCG is cheaper at 0.06% per year. On volatility, IMCG has been the lower-risk option at 4.65%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, IMCG has performed better with a 8.62% return vs 8.25%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
IMCG is cheaper with a 0.06% expense ratio, compared with 0.80% for BOUT.
IMCG has the higher dividend yield at 0.65%, compared with 0.26% for BOUT.
BOUT tracks IBD Breakout Stocks Total Return Index, while IMCG tracks Morningstar US Mid Cap Broad Growth Index. They also come from different issuers: Innovator and iShares. Their fees differ too: 0.80% for BOUT and 0.06% for IMCG.
BOUT currently has the higher Sharpe Ratio (1.71 vs 1.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BOUT and IMCG
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer